Scientific reports
Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study.
Charlène Lefèvre, Théo Funck-Brentano, Marine Cachanado, Alexia Plocque, Maëlle Youinou, Audrey Fels, Frédéric Pène, Laurent Savale, David Montani, Olivier Voisin, Flore Bintein, Lucille Wildenberg, Axel Philippe, Stéphane Legriel, Nicolas Roche
Published: 202610.1038/s41598-026-36864-w
Abstract
During severe and critical COVID-19, therapeutic options remain scarce. Among interventions, the use of interleukin-6 receptor inhibitor (IL-6Ri) is especially controversial due to persistent uncertainty about their efficacy and safety. To compare th…
Preview only. Read the full abstract at the source